APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD86 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD86 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchCD86 Antibody Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal CD86 Antibody Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal CD86 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD86 Antibody Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal CD86 Antibody Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CD86 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD86 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD86 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD86 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD86 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD86 Antibody market include Thermo Fisher Scientific, United States Biological, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, Miltenyi Biotec, FineTest and EXBIO, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD86 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD86 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD86 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD86 Antibody market.

CD86 Antibody Segment by Company

Thermo Fisher Scientific

United States Biological

Santa Cruz Biotechnology

Proteintech

ProSci

NSJ Bioreagents

Miltenyi Biotec

FineTest

EXBIO

Bio-Rad

BioLegend

Bio X Cell

Bethyl

Beckman Coulter

CD86 Antibody Segment by Type

Polyclonal

Monoclonal

CD86 Antibody Segment by Application

Immunohistochemistry

Enzyme Linked Immunosorbent Assay

Flow Cytometry

Western Blot

Others

CD86 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CD86 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD86 Antibody key companies, revenue, market share, and recent developments.

3. To split the CD86 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD86 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD86 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CD86 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD86 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD86 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD86 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD86 Antibody industry.

Chapter 3: Detailed analysis of CD86 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD86 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD86 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD86 Antibody Industry Trends Table 2. CD86 Antibody Industry Drivers Table 3. CD86 Antibody Industry Opportunities and Challenges Table 4. CD86 Antibody Industry Restraints Table 5. Global CD86 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD86 Antibody Revenue Share by Company (2021-2026) Table 7. Global CD86 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD86 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global CD86 Antibody Company, Product Type & Application Table 10. Global CD86 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD86 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global CD86 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CD86 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CD86 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CD86 Antibody Sales Value Share by Type (2021-2026) Table 20. Global CD86 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Table 22. Significant Companies of Enzyme Linked Immunosorbent Assay Table 23. Significant Companies of Flow Cytometry Table 24. Significant Companies of Western Blot Table 25. Significant Companies of Others Table 26. Global CD86 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CD86 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global CD86 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global CD86 Antibody Sales Value Share by Application (2021-2026) Table 30. Global CD86 Antibody Sales Value Share by Application (2027-2032) Table 31. Global CD86 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CD86 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global CD86 Antibody Sales Value Share by Region (2021-2026) Table 34. Global CD86 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global CD86 Antibody Sales Value Share by Region (2027-2032) Table 36. Global CD86 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global CD86 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global CD86 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global CD86 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global CD86 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific CD86 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. United States Biological Company Information Table 47. United States Biological Business Overview Table 48. United States Biological CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. United States Biological CD86 Antibody Product Portfolio Table 50. United States Biological Recent Development Table 51. Santa Cruz Biotechnology Company Information Table 52. Santa Cruz Biotechnology Business Overview Table 53. Santa Cruz Biotechnology CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Santa Cruz Biotechnology CD86 Antibody Product Portfolio Table 55. Santa Cruz Biotechnology Recent Development Table 56. Proteintech Company Information Table 57. Proteintech Business Overview Table 58. Proteintech CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Proteintech CD86 Antibody Product Portfolio Table 60. Proteintech Recent Development Table 61. ProSci Company Information Table 62. ProSci Business Overview Table 63. ProSci CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. ProSci CD86 Antibody Product Portfolio Table 65. ProSci Recent Development Table 66. NSJ Bioreagents Company Information Table 67. NSJ Bioreagents Business Overview Table 68. NSJ Bioreagents CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. NSJ Bioreagents CD86 Antibody Product Portfolio Table 70. NSJ Bioreagents Recent Development Table 71. Miltenyi Biotec Company Information Table 72. Miltenyi Biotec Business Overview Table 73. Miltenyi Biotec CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Miltenyi Biotec CD86 Antibody Product Portfolio Table 75. Miltenyi Biotec Recent Development Table 76. FineTest Company Information Table 77. FineTest Business Overview Table 78. FineTest CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. FineTest CD86 Antibody Product Portfolio Table 80. FineTest Recent Development Table 81. EXBIO Company Information Table 82. EXBIO Business Overview Table 83. EXBIO CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. EXBIO CD86 Antibody Product Portfolio Table 85. EXBIO Recent Development Table 86. Bio-Rad Company Information Table 87. Bio-Rad Business Overview Table 88. Bio-Rad CD86 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bio-Rad CD86 Antibody Product Portfolio Table 90. Bio-Rad Recent Development Table 91. BioLegend Company Information Table 92. BioLegend Business Overview Table 93. BioLegend CD86 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. BioLegend CD86 Antibody Product Portfolio Table 95. BioLegend Recent Development Table 96. Bio X Cell Company Information Table 97. Bio X Cell Business Overview Table 98. Bio X Cell CD86 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bio X Cell CD86 Antibody Product Portfolio Table 100. Bio X Cell Recent Development Table 101. Bethyl Company Information Table 102. Bethyl Business Overview Table 103. Bethyl CD86 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Bethyl CD86 Antibody Product Portfolio Table 105. Bethyl Recent Development Table 106. Beckman Coulter Company Information Table 107. Beckman Coulter Business Overview Table 108. Beckman Coulter CD86 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Beckman Coulter CD86 Antibody Product Portfolio Table 110. Beckman Coulter Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. CD86 Antibody Product Image Figure 2. Global CD86 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD86 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global CD86 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global CD86 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CD86 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CD86 Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Image Figure 13. Enzyme Linked Immunosorbent Assay Image Figure 14. Flow Cytometry Image Figure 15. Western Blot Image Figure 16. Others Image Figure 17. Global CD86 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CD86 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global CD86 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global CD86 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global CD86 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America CD86 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America CD86 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe CD86 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe CD86 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific CD86 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific CD86 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America CD86 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America CD86 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa CD86 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa CD86 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt CD86 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt CD86 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt CD86 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry
  • Enzyme Linked Immunosorbent Assay
  • Flow Cytometry
  • Western Blot
  • Others
Companies covered
  • Thermo Fisher Scientific
  • United States Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • ProSci
  • NSJ Bioreagents
  • Miltenyi Biotec
  • FineTest
  • EXBIO
  • Bio-Rad
  • BioLegend
  • Bio X Cell
  • Bethyl
  • Beckman Coulter

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD86 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD86 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD86 Antibody Market Dynamics
  1. 2.1 CD86 Antibody Industry Trends
  2. 2.2 CD86 Antibody Industry Drivers
  3. 2.3 CD86 Antibody Industry Opportunities and Challenges
  4. 2.4 CD86 Antibody Industry Restraints
3 CD86 Antibody Market by Company
  1. 3.1 Global CD86 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CD86 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CD86 Antibody Company Ranking (2024-2026)
  4. 3.4 Global CD86 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global CD86 Antibody Company Product Type and Application
  6. 3.6 Global CD86 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD86 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD86 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD86 Antibody Market by Type
  1. 4.1 CD86 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global CD86 Antibody Sales Value by Type
  5. 4.2.1 Global CD86 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CD86 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global CD86 Antibody Sales Value Share by Type (2021-2032)
5 CD86 Antibody Market by Application
  1. 5.1 CD86 Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry
  3. 5.1.2 Enzyme Linked Immunosorbent Assay
  4. 5.1.3 Flow Cytometry
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global CD86 Antibody Sales Value by Application
  8. 5.2.1 Global CD86 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CD86 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global CD86 Antibody Sales Value Share by Application (2021-2032)
6 CD86 Antibody Regional Value Analysis
  1. 6.1 Global CD86 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD86 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD86 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD86 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD86 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America CD86 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD86 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe CD86 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD86 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD86 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD86 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America CD86 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD86 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD86 Antibody Sales Value Share by Country, 2025 VS 2032
7 CD86 Antibody Country-level Value Analysis
  1. 7.1 Global CD86 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD86 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD86 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD86 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD86 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD86 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD86 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD86 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD86 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD86 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD86 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD86 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD86 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD86 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD86 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD86 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD86 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD86 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD86 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD86 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD86 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD86 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD86 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD86 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD86 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD86 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD86 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD86 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD86 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD86 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD86 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD86 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD86 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD86 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD86 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific CD86 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific CD86 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 United States Biological
  8. 8.2.1 United States Biological Company Information
  9. 8.2.2 United States Biological Business Overview
  10. 8.2.3 United States Biological CD86 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 United States Biological CD86 Antibody Product Portfolio
  12. 8.2.5 United States Biological Recent Developments
  13. 8.3 Santa Cruz Biotechnology
  14. 8.3.1 Santa Cruz Biotechnology Company Information
  15. 8.3.2 Santa Cruz Biotechnology Business Overview
  16. 8.3.3 Santa Cruz Biotechnology CD86 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Santa Cruz Biotechnology CD86 Antibody Product Portfolio
  18. 8.3.5 Santa Cruz Biotechnology Recent Developments
  19. 8.4 Proteintech
  20. 8.4.1 Proteintech Company Information
  21. 8.4.2 Proteintech Business Overview
  22. 8.4.3 Proteintech CD86 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Proteintech CD86 Antibody Product Portfolio
  24. 8.4.5 Proteintech Recent Developments
  25. 8.5 ProSci
  26. 8.5.1 ProSci Company Information
  27. 8.5.2 ProSci Business Overview
  28. 8.5.3 ProSci CD86 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ProSci CD86 Antibody Product Portfolio
  30. 8.5.5 ProSci Recent Developments
  31. 8.6 NSJ Bioreagents
  32. 8.6.1 NSJ Bioreagents Company Information
  33. 8.6.2 NSJ Bioreagents Business Overview
  34. 8.6.3 NSJ Bioreagents CD86 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NSJ Bioreagents CD86 Antibody Product Portfolio
  36. 8.6.5 NSJ Bioreagents Recent Developments
  37. 8.7 Miltenyi Biotec
  38. 8.7.1 Miltenyi Biotec Company Information
  39. 8.7.2 Miltenyi Biotec Business Overview
  40. 8.7.3 Miltenyi Biotec CD86 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Miltenyi Biotec CD86 Antibody Product Portfolio
  42. 8.7.5 Miltenyi Biotec Recent Developments
  43. 8.8 FineTest
  44. 8.8.1 FineTest Company Information
  45. 8.8.2 FineTest Business Overview
  46. 8.8.3 FineTest CD86 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 FineTest CD86 Antibody Product Portfolio
  48. 8.8.5 FineTest Recent Developments
  49. 8.9 EXBIO
  50. 8.9.1 EXBIO Company Information
  51. 8.9.2 EXBIO Business Overview
  52. 8.9.3 EXBIO CD86 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 EXBIO CD86 Antibody Product Portfolio
  54. 8.9.5 EXBIO Recent Developments
  55. 8.10 Bio-Rad
  56. 8.10.1 Bio-Rad Company Information
  57. 8.10.2 Bio-Rad Business Overview
  58. 8.10.3 Bio-Rad CD86 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bio-Rad CD86 Antibody Product Portfolio
  60. 8.10.5 Bio-Rad Recent Developments
  61. 8.11 BioLegend
  62. 8.11.1 BioLegend Company Information
  63. 8.11.2 BioLegend Business Overview
  64. 8.11.3 BioLegend CD86 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioLegend CD86 Antibody Product Portfolio
  66. 8.11.5 BioLegend Recent Developments
  67. 8.12 Bio X Cell
  68. 8.12.1 Bio X Cell Company Information
  69. 8.12.2 Bio X Cell Business Overview
  70. 8.12.3 Bio X Cell CD86 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bio X Cell CD86 Antibody Product Portfolio
  72. 8.12.5 Bio X Cell Recent Developments
  73. 8.13 Bethyl
  74. 8.13.1 Bethyl Company Information
  75. 8.13.2 Bethyl Business Overview
  76. 8.13.3 Bethyl CD86 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bethyl CD86 Antibody Product Portfolio
  78. 8.13.5 Bethyl Recent Developments
  79. 8.14 Beckman Coulter
  80. 8.14.1 Beckman Coulter Company Information
  81. 8.14.2 Beckman Coulter Business Overview
  82. 8.14.3 Beckman Coulter CD86 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Beckman Coulter CD86 Antibody Product Portfolio
  84. 8.14.5 Beckman Coulter Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst